Shares of Ocugen Inc. OCGN slid 1.91% to $0.72 Thursday, on what proved to be an all-around rough trading session for the ...
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...
On Thursday, Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.71 which represents a decrease of $-0.02 or -2.74% from the prior close of $0.73. The stock opened at $0.74 and touched a low ...
Ocugen (OCGN) announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema, DME. “OCU200 has ...
Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of the second phase of the Phase 1/2 OCU410 ArMaDa clinical trial for treating geographic atrophy (GA ...
Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.83 which represents a decrease of $-0.05 or -5.68% from the prior close of $0.88. The stock opened at $0.87 and touched a low of $0.82 ...
Ocugen Inc. closed $1.23 below its 52-week high ($2.11), which the company reached on March 25th.
Hosted on MSN4d
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis PigmentosaMALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback